|
Mar 19
|
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
|
|
Mar 19
|
Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
|
|
Mar 19
|
UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
|
|
Mar 19
|
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
|
|
Mar 12
|
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
|
|
Mar 11
|
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 15
|
Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc
|
|
Feb 14
|
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
|
|
Feb 12
|
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 13
|
Crinetics Pharmaceuticals Inc Insider Sells Shares
|
|
Jan 10
|
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 5
|
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ...
|
|
Jan 4
|
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
|
|
Dec 29
|
Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares
|
|
Dec 23
|
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...
|
|
Dec 18
|
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
|
|
Dec 3
|
12 Stocks Billionaire Steve Cohen Just Bought and Sold
|
|
Sep 15
|
Why Crinetics Pharmaceuticals Stock Soared This Week
|
|
Sep 13
|
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
|
|
Sep 11
|
Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63%
|